ArticleMolecular therapy. Nucleic acids2026
Rabies lyssavirus phosphoprotein possesses RNA duplex-unwinding activities.
Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A new role for an old player: The rabies virus phosphoprotein as an RNA chaperone, helicase, and immune evasion hub.Molecular therapy. Nucleic acids · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rabies lyssavirus (RABV) is a prototypical neurotropic virus that belongs to the Rhabdoviridae family and causes one of the most lethal zoonotic diseases. For RNA viruses, RNA-unwinding proteins such as helicases and RNA chaperones are crucial for the replication and/or correct folding of viral RNAs. Although numerous RNA viruses have been found to encode their RNA-unwinding proteins, no RNA-unwinding activity has been identified in the family Rhabdoviridae. Herein, we uncovered that RABV phosphoprotein (RABV-P) possesses both a nucleoside triphosphate (NTP)-dependent helicase-like RNA duplex-unwinding activity and an NTP-independent duplex-unwinding and annealing activity. The C-terminal domain of RABV-P is required for its RNA-unwinding activities, whereas the NTP-dependent helicase-like unwinding activity also relies on its central oligomerization domain (COD). Furthermore, we designed two peptides (named P90 and P110) to target the COD and revealed that these peptides effectively inhibited RABV replication in cells. Overall, the study provides the first demonstration of the RNA helicase-like and NTP-independent RNA-unwinding/annealing activities associated with a rhabdovirus-encoded protein. This study highlights the functional significance of P in the RABV life cycle and probably other rhabdoviruses, and targeting RABV-P represents a promising strategy for developing novel antivirals against this lethal pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.